REDWOOD CITY, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. announced today that the company will be webcasting its corporate presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on Wednesday, November 7th at 8:50 am Eastern Time. The webcast can be accessed through the Investor Information section of the company’s web site at http://www.Genelabs.com.
About Genelabs Technologies
Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit http://www.genelabs.com.
Note: Genelabs(R) and the Genelabs logo are registered trademarks of Genelabs Technologies, Inc.
Contact: James A. D. Smith
CONTACT: James A. D. Smith, President and Chief Executive Officer of
Genelabs Technologies, Inc., +1-650-562-1424
Web site: http://www.Genelabs.com/
